posters
Immuno-Onoclogy Summit 2022 Posters
Check out the latest data on patient-derived organoids for immunotherapy development
posters
Check out the latest data on patient-derived organoids for immunotherapy development
posters
Check out the latest data on patient-derived organoids that HUB presented at ELRIG drug discovery meeting in 2022.
posters
Drug toxicology studies are essential for assessing drug safety and represent a pivotal step in the preclinical stages of drug...
case study
Proof-of-concept study highlighting how HUB Organoids® can be used to accelerate your preclinical drug development timeline to just about five...
fact sheets
Immunotherapy has shown substantial success in cancer treatment, however its efficacy is limited to only a subset of patients.
fact sheets
Immuno-oncology (IO) therapy is a rapidly evolving treatment strategy to combat cancer
fact sheets
Safety-related problems continue to be one of them major causes of drug attrition in preclinical and clinical development. Preclinical safety...
posters
Cystic fibrosis (CF) patient prognosis has recently improved due to the development of new, more effective treatments and better combination...
news and insights
The study identifies the first clinical candidate developed using HUB Organoids® and high-content screening that inhibits tumor growth and metastasis...
fact sheets
HUB Organoid Technology represents a breakthrough in stem cell research and has allowed to gain better understanding in fields like...
posters
Adult epithelial stem cell-derived organoids (HUB Organoids™) are proving to be a major breakthrough in preclinical models. HUB Organoids are...
posters
Colorectal cancer (CRC) is the third leading cause of cancer and cancer-related death. A large fraction of the CRC patients...
posters
Poster P03: Autologous organoid and T cell co-cultures as a powerful personalized platform for Immunotherapy development
info sheets
A vast collection of established patient-derived models. The HUB Organoid Biobank includes more than a thousand of established organoid models...
news and insights
Leiden, The Netherlands, May 3, 2022 – MIMETAS, a global leader in Organ-on-a-Chip models and technology, announces today that it has...
news and insights
San Diego, California, April 28, 2022 – Crown Bioscience, a JSR Life Sciences company, and HUB Organoids (HUB) announced today the publication of...
news and insights
Our Carla Verissimo, Head of Oncology II speaks about the current challenges of oncology drug development in this exclusive interview...
news and insights
2 September 2021, Utrecht (The Netherlands) - Hubrecht Organoid Technology (HUB) joins a new international consortium of academic and industrial...
paper
HUB Organoids® derived from patients with chronic hepatitis B show the first molecular signs of liver cancer. The molecular events...
news and insights
VANCOUVER, British Columbia - STEMCELL Technologies and Hubrecht Organoid Technology (HUB) have announced that they have signed an agreement for...
fact sheets
Safety-related problems continue to be one of the major causes of drug attrition in preclinical and clinical development. Preclinical safety...
paper
HUB Organoids® supports the on-going clinical evaluation of ELX-02 as a therapeutic agent for cystic fibrosis (CF). HUB Organoids advance...
paper
Discover the development of a new model to assess drug safety, absorption, methabolism, transport, and permeability. Compromised intestinal barrier function...
news and insights
HUB takes centre stage during this year’s Olympic games in Tokyo by sponsoring the Innovation Parade, an online event organized by the Embassy of the Kingdom...
news and insights
April 26, 2021 - Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today continuation of their collaboration...
news and insights
Utrecht and Qingdao, Sep 4th, 2020 – Hubrecht Organoid Technology (HUB) and BGI-Qingdao announced today that they have signed a Memorandum of Understanding (MoU) to...
news and insights
Researchers from the group of Hans Clevers at the Hubrecht Institute have modeled the development and progression of high-grade serous...
posters
Discover how to reduce costly animal experiments and obtain a quick indication of your drug safety with Merel Derksen. Poster 391: Intestinal organoids as in...
posters
Dr. Pourfarzad presents data on the use of HUB Organoids as advanced modes to investigate ADME and safety. Poster 553: HUB Organoids™ improve preclinical toxicology,...
fact sheets
Advances in immunotherapy have revolutionized cancer treatment over the past few years – reflecting the importance of the interaction between...
fact sheets
Cystic fibrosis (CF) is a genetic disease that is caused by mutations of the gene encoding for Cystic Fibrosis Transmembrane...
news and insights
Hormone-producing cells in the human gut are difficult to study, as they are very rare and unique to different species...
news and insights
Researchers from the Hubrecht Institute in Utrecht, Erasmus MC University Medical Center Rotterdam, and Maastricht University in the Netherlands have...
news and insights
Dear Valued Customer, On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak....
news and insights
Whereas the CRISPR/Cas9 technology cuts out a defect in a gene and replaces it with a new piece, the latest...
news and insights
On December 10, 2019 the Financial Times featured HUB Organoids™ in an article titled “Organoid innovation offers potential for cancer...
ON-DEMAND PRESENTATION
Drug discovery and development is a lengthy process, often starting with the identification of new drug targets – based on...
ON-DEMAND PRESENTATION
New online presentation available on the use of HUB Organoids™ as a revolutionary approach to disease modeling, drug screening, and...
ON-DEMAND PRESENTATION
Our CEO Dr. Rob Vries discusses how HUB Organoids help modelling human disease and select best treatement options. Classic in...
news and insights
San Diego, October 17, 2019 – Crown Bioscience today announced the launch of a new tumor organoid drug development platform...
news and insights
Leiden, Utrecht September 2019 - MIMETAS and Hubrecht Organoid Technology (HUB) announce that they entered into a strategic collaboration to...
news and insights
Manchester, 16th July, 2019 - Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of...
ON-DEMAND PRESENTATION
Watch Dr. Sylvia Boj discussing how HUB Organoids accelerate the development of new therapeutics for inflammatory diseases. The lack of...
white papers
Oncology drug development is especially risky with only 5% of new compounds reaching market approval. The lack of patient-relevant, early-stage...
fact sheets
HUB Organoids™ are unique patient-derived in vitro models developed directly from patient biopsies or resections.
application notes
HUB was founded by the Hubrecht Institute, the University Medical Center Utrecht, and the Royal Netherlands Academy of Arts and...
news and insights
San Diego, Calif – May 19, 2020 — Crown Bioscience today announced the expansion of their unique organoid platform with the addition of 130 Hubrecht...
ON-DEMAND PRESENTATION
Dr. Vries joins the monthly seminar series organized by the Personalized Health Basel (PHB) initiative. Personalized medicine holds great promise for the future of patient treatment,...
news and insights
March 27, 2019 – Hubrecht Organoid Technology (HUB) and JSR Corporation, the parent company, of Crown Bioscience, entered into a...
ON-DEMAND PRESENTATION
HUB Organoids as models for precision medicine, in vitro diagnostics, and infectious disease. During this virtual mini-symposium co-hosted with our...
news and insights
February 1, 2019 – Hubrecht Organoid Technology (HUB) and Yamaha Motor Co., Ltd. (Tokyo:7272) announced today their collaboration to provide...
